Skip to main content

Table 2 Clinical characteristics and EHPX1 methylation in the 25 patients with CBZ-sensitive epilepsy

From: Different EPHX1 methylation levels in promoter area between carbamazepine-resistant epilepsy group and carbamazepine-sensitive epilepsy group in Chinese population

ID No.

Gender

Age

Final-dose (mg)

CBZ-concentration

in blood (ug/ml)

CBZ-concentration

/ Final dose (Ratio)

Seizure-frequency

Course of disease (year)

EHPX1 methylation

1

M

45

600

8.3

14.1/1000

1–2/year

4

32%

2

F

38

400

4.1

10.2/1000

2–3/year

5

6%

3

F

46

700

6.4

8.9/1000

1/year

3

28%

4

M

41

600

7.2

12.2/1000

4

25%

5

M

35

800

6.8

8.5/1000

4

27%

6

M

37

200

2.6

13.0/1000

2–3/year

5

24%

7

F

40

600

5.7

9.7/1000

1–2/year

6

23%

8

F

43

600

5.3

9.0/1000

4

16%

9

M

48

800

7.2

9.0/1000

1–2/year

5

12%

10

M

39

600

5.6

9.5/1000

2

27%

11

F

43

600

5.2

10.9/1000

2

32%

12

F

50

700

6.4

8.9/1000

1–2/year

3

24%

13

F

47

600

5.7

9.7/1000

1–2/year

1

11%

14

M

52

600

6.4

10.9/1000

3

13%

15

F

33

800

7.5

9.4/1000

3–4/year

4

17%

16

M

54

700

7.1

9.9/1000

2–3/year

2

20%

17

M

36

600

6.7

11.4/1000

3

24%

18

M

38

600

6.8

11.6/1000

2

28%

19

F

40

600

5.5

9.4/1000

1–2/year

6

16%

20

M

42

400

4.6

11.5/1000

4

30%

21

F

44

600

5.5

9.4/1000

2–3/year

3

26%

22

M

48

400

4.7

11.8/1000

4

22%

23

F

39

400

4.9

12.3/1000

3

17%

24

M

36

700

6.0

8.4/1000

1–2/year

3

20%

25

F

47

600

5.9

10.0/1000

1–2/year

2

14%